Disease progression and early viral dynamics in human immunodeficiency virus-infected children exposed to zidovudine during prenatal and perinatal periods

Louise Kuhn, Elaine J. Abrams, Jeremy Weedon, Genevieve Lambert, Ellie Schoenbaum, Steve R. Nesheim, Paul Palumbo, Peter E. Vink, Marc Bulterys

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Zidovudine (Zdv) is widely used to reduce maternal-infant human immunodeficiency virus transmission (HIV), but its consequences for disease progression among children infected despite Zdv exposure remain unknown. In a multicenter observational cohort study of 325 HIV-infected children born during 1986-1997, clinical progression was compared among infected children exposed or unexposed to Zdv during prenatal and perinatal periods. Zdv exposure was associated with 1.8-fold (95% confidence interval, 1.02-3.11) increased risk of progressing to AIDS or death after adjusting for year of birth, maternal CD4 cell count, maternal AIDS diagnosis, and subsequent antiretroviral therapy of the child. Mean log10 viral copies at 7-12 weeks were higher among Zdv-exposed children (P = .004). No infected child treated early with multidrug therapy progressed to AIDS or died by 1 year, regardless of early Zdv exposure. More rapid disease progression was observed among infected children exposed during pregnancy or birth to Zdv if effective multidrug therapy was not initiated.

Original languageEnglish (US)
Pages (from-to)104-111
Number of pages8
JournalJournal of Infectious Diseases
Volume182
Issue number1
DOIs
StatePublished - 2000

Fingerprint

Zidovudine
Disease Progression
HIV
Acquired Immunodeficiency Syndrome
Mothers
Parturition
CD4 Lymphocyte Count
Observational Studies
Cohort Studies
Therapeutics
Confidence Intervals
Pregnancy

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Disease progression and early viral dynamics in human immunodeficiency virus-infected children exposed to zidovudine during prenatal and perinatal periods. / Kuhn, Louise; Abrams, Elaine J.; Weedon, Jeremy; Lambert, Genevieve; Schoenbaum, Ellie; Nesheim, Steve R.; Palumbo, Paul; Vink, Peter E.; Bulterys, Marc.

In: Journal of Infectious Diseases, Vol. 182, No. 1, 2000, p. 104-111.

Research output: Contribution to journalArticle

Kuhn, Louise ; Abrams, Elaine J. ; Weedon, Jeremy ; Lambert, Genevieve ; Schoenbaum, Ellie ; Nesheim, Steve R. ; Palumbo, Paul ; Vink, Peter E. ; Bulterys, Marc. / Disease progression and early viral dynamics in human immunodeficiency virus-infected children exposed to zidovudine during prenatal and perinatal periods. In: Journal of Infectious Diseases. 2000 ; Vol. 182, No. 1. pp. 104-111.
@article{fa3711924394491a96e2deb90fb7a704,
title = "Disease progression and early viral dynamics in human immunodeficiency virus-infected children exposed to zidovudine during prenatal and perinatal periods",
abstract = "Zidovudine (Zdv) is widely used to reduce maternal-infant human immunodeficiency virus transmission (HIV), but its consequences for disease progression among children infected despite Zdv exposure remain unknown. In a multicenter observational cohort study of 325 HIV-infected children born during 1986-1997, clinical progression was compared among infected children exposed or unexposed to Zdv during prenatal and perinatal periods. Zdv exposure was associated with 1.8-fold (95{\%} confidence interval, 1.02-3.11) increased risk of progressing to AIDS or death after adjusting for year of birth, maternal CD4 cell count, maternal AIDS diagnosis, and subsequent antiretroviral therapy of the child. Mean log10 viral copies at 7-12 weeks were higher among Zdv-exposed children (P = .004). No infected child treated early with multidrug therapy progressed to AIDS or died by 1 year, regardless of early Zdv exposure. More rapid disease progression was observed among infected children exposed during pregnancy or birth to Zdv if effective multidrug therapy was not initiated.",
author = "Louise Kuhn and Abrams, {Elaine J.} and Jeremy Weedon and Genevieve Lambert and Ellie Schoenbaum and Nesheim, {Steve R.} and Paul Palumbo and Vink, {Peter E.} and Marc Bulterys",
year = "2000",
doi = "10.1086/315678",
language = "English (US)",
volume = "182",
pages = "104--111",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Disease progression and early viral dynamics in human immunodeficiency virus-infected children exposed to zidovudine during prenatal and perinatal periods

AU - Kuhn, Louise

AU - Abrams, Elaine J.

AU - Weedon, Jeremy

AU - Lambert, Genevieve

AU - Schoenbaum, Ellie

AU - Nesheim, Steve R.

AU - Palumbo, Paul

AU - Vink, Peter E.

AU - Bulterys, Marc

PY - 2000

Y1 - 2000

N2 - Zidovudine (Zdv) is widely used to reduce maternal-infant human immunodeficiency virus transmission (HIV), but its consequences for disease progression among children infected despite Zdv exposure remain unknown. In a multicenter observational cohort study of 325 HIV-infected children born during 1986-1997, clinical progression was compared among infected children exposed or unexposed to Zdv during prenatal and perinatal periods. Zdv exposure was associated with 1.8-fold (95% confidence interval, 1.02-3.11) increased risk of progressing to AIDS or death after adjusting for year of birth, maternal CD4 cell count, maternal AIDS diagnosis, and subsequent antiretroviral therapy of the child. Mean log10 viral copies at 7-12 weeks were higher among Zdv-exposed children (P = .004). No infected child treated early with multidrug therapy progressed to AIDS or died by 1 year, regardless of early Zdv exposure. More rapid disease progression was observed among infected children exposed during pregnancy or birth to Zdv if effective multidrug therapy was not initiated.

AB - Zidovudine (Zdv) is widely used to reduce maternal-infant human immunodeficiency virus transmission (HIV), but its consequences for disease progression among children infected despite Zdv exposure remain unknown. In a multicenter observational cohort study of 325 HIV-infected children born during 1986-1997, clinical progression was compared among infected children exposed or unexposed to Zdv during prenatal and perinatal periods. Zdv exposure was associated with 1.8-fold (95% confidence interval, 1.02-3.11) increased risk of progressing to AIDS or death after adjusting for year of birth, maternal CD4 cell count, maternal AIDS diagnosis, and subsequent antiretroviral therapy of the child. Mean log10 viral copies at 7-12 weeks were higher among Zdv-exposed children (P = .004). No infected child treated early with multidrug therapy progressed to AIDS or died by 1 year, regardless of early Zdv exposure. More rapid disease progression was observed among infected children exposed during pregnancy or birth to Zdv if effective multidrug therapy was not initiated.

UR - http://www.scopus.com/inward/record.url?scp=0033928014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033928014&partnerID=8YFLogxK

U2 - 10.1086/315678

DO - 10.1086/315678

M3 - Article

VL - 182

SP - 104

EP - 111

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -